Literature DB >> 25450034

Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.

Andrew J Cowan1, Yoshio Inoue2, Evan Y Yu3.   

Abstract

Entities:  

Keywords:  Castration-resistant; Clinical trials; Combined androgen blockade; Prostate cancer; Prostate-specific antigen

Mesh：

Substances：

Year:  2014        PMID： 25450034      PMCID： PMC4289435          DOI： 10.1016/j.clgc.2014.08.015

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  28 in total

Review 1.  Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.

Authors:  R N Brogden; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

2.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Authors:  E D Crawford; M A Eisenberger; D G McLeod; J T Spaulding; R Benson; F A Dorr; B A Blumenstein; M A Davis; P J Goodman
Journal:  N Engl J Med       Date:  1989-08-17       Impact factor: 91.245

Review 3.  Bicalutamide: clinical pharmacokinetics and metabolism.

Authors:  Ian D Cockshott
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

Authors:  H I Scher; W K Kelly
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

5.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Authors:  Mary-Ellen Taplin; Barur Rajeshkumar; Susan Halabi; Cary P Werner; Bruce A Woda; Joel Picus; Walter Stadler; Daniel F Hayes; Philip W Kantoff; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

6.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

Authors:  Takahito Hara; Jun-ichi Miyazaki; Hideo Araki; Masuo Yamaoka; Naoyuki Kanzaki; Masami Kusaka; Masaomi Miyamoto
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Authors:  Eric J Small; Susan Halabi; Nancy A Dawson; Walter M Stadler; Brian I Rini; Joel Picus; Preston Gable; Frank M Torti; Ellen Kaplan; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

9.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

10.  Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.

Authors:  W K Kelly; H I Scher
Journal:  J Urol       Date:  1993-03       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.